NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSXV: NBM) (OTC: NBMFF), a low-cost, silicon-enhanced battery developer ...
Zacks Investment Research on MSN
Can BMY's growth portfolio drive top-line expansion in 2026?
Bristol Myers Squibb’s BMY performance in 2025 reflects an ongoing transition in its revenue base, with growth from newer ...
Opinion
14hOpinion
AI Integration In MedTech Devices And Diagnostics: Regulation And Investment Opportunities
GE HealthCare Technologies Inc. (NYSE: GEHC) leads with 100 FDA-approved AI devices, concentrating heavily on imaging and diagnostics. Their CleaRecon DL technology sharpens cone-beam CT images using ...
Zacks Investment Research on MSN
KRMD submits 510(k) to use FreedomEDGE system with oncology biologic
KORU Medical Systems, Inc.KRMD recently announced that it has submitted a 510(k) premarket notification for FDA clearance to ...
When a biotech company announces positive Phase 3 trial results or receives FDA approval, the market reaction is often immediate and substantial. This is not just speculation. These milestones ...
The FDA has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program. This is an expanded access program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback